{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:59:26Z","timestamp":1793401166671,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40123-026-01344-x","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:05:14Z","timestamp":1772636714000},"page":"1375-1388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["One-Year Real-World Outcomes of Switching to Aflibercept 8\u00a0mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report"],"prefix":"10.1007","volume":"15","author":[{"given":"Alice M.","family":"Kitay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bonanata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahm","family":"Spitznagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Gabathuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolo","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Magnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"L\u00f6liger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Menghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor M\u00e1rk","family":"Somfai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Zweifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara M.","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-5082","authenticated-orcid":false,"given":"Justus G.","family":"Garweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaika M.","family":"Kurz-Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"2","key":"1344_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331(2):147\u201357.","journal-title":"JAMA"},{"issue":"15","key":"1344_CR2","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","volume":"291","author":"NM Bressler","year":"2004","unstructured":"Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900\u20131.","journal-title":"JAMA"},{"key":"1344_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-10-31","volume":"10","author":"U Chakravarthy","year":"2010","unstructured":"Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010;10:31.","journal-title":"BMC Ophthalmol"},{"issue":"9827","key":"1344_CR4","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728\u201338.","journal-title":"Lancet"},{"key":"1344_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2147\/DDDT.S40215","volume":"7","author":"F Semeraro","year":"2013","unstructured":"Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C. Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther. 2013;7:711\u201322.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"1344_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1120672119832432","volume":"29","author":"Z Papadopoulos","year":"2019","unstructured":"Papadopoulos Z. Aflibercept: a review of its effect on the treatment of exudative age-related macular degeneration. Eur J Ophthalmol. 2019;29(4):368\u201378.","journal-title":"Eur J Ophthalmol"},{"issue":"11","key":"1344_CR7","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1038\/s41433-025-03829-8","volume":"39","author":"JI Lim","year":"2025","unstructured":"Lim JI, Ko S, McAllister M, Faux N, Bawa K, Mearns E, et al. Systematic review of clinical practice guidelines for the management of neovascular age-related macular degeneration. Eye Lond. 2025;39(11):2223\u201330.","journal-title":"Eye Lond"},{"issue":"9","key":"1344_CR8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141(9):834\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"1344_CR9","doi-asserted-by":"crossref","unstructured":"Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration: 96-week results from the randomized phase 3 PULSAR trial. Ophthalmology. 2025.","DOI":"10.1016\/S0140-6736(24)00063-1"},{"issue":"10432","key":"1344_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352.","journal-title":"Lancet"},{"issue":"8","key":"1344_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.oret.2025.02.002","volume":"9","author":"S Bala","year":"2025","unstructured":"Bala S, Barbosa GCS, Mohan N, Srivastava SK, Kaiser PK, Sastry A, et al. Initial functional and anatomical outcomes of high-dose aflibercept 8 mg in exudative neovascular age-related macular degeneration. Ophthalmol Retina. 2025;9(8):756\u201366.","journal-title":"Ophthalmol Retina"},{"key":"1344_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-002091","author":"D Sambhara","year":"2025","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA. Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol. 2025. https:\/\/doi.org\/10.1136\/bmjophth-2024-002091.","journal-title":"BMJ Open Ophthalmol"},{"key":"1344_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/life15060903","author":"M Musadiq","year":"2025","unstructured":"Musadiq M, Musadiq M, Latif F, Ng B, Azzopardi M, Gilead N, et al. Early real-world outcomes of switching to 8 mg aflibercept for neovascular age-related macular degeneration in the United Kingdom. Life. 2025. https:\/\/doi.org\/10.3390\/life15060903.","journal-title":"Life"},{"key":"1344_CR14","unstructured":"Gr\u00fcn M, Rothaus K, Lommatzsch AP, Faatz H. [Erste Real-World-Erfahrungen mit Aflibercept 8 mg bei der Behandlung der neovaskul\u00e4ren AMD]. Klin Monbl Augenheilkd. 2025."},{"issue":"1","key":"1344_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00665-6","volume":"11","author":"J Cattaneo","year":"2025","unstructured":"Cattaneo J, De Oliveira Figueiredo EC, Montesel A, Vermeirsch S, Eandi CM. Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Na\u00efve neovascular AMD: AI-assisted fluid volume analysis. Int J Retina Vitreous. 2025;11(1):42.","journal-title":"Int J Retina Vitreous"},{"issue":"6","key":"1344_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamaophthalmol.2025.0969","volume":"143","author":"KE Binder","year":"2025","unstructured":"Binder KE, Bleidi\u00dfel N, Charbel Issa P, Maier M, Coulibaly LM. Noninfectious intraocular inflammation after intravitreal aflibercept. JAMA Ophthalmol. 2025;143(6):499\u2013506.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1344_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03788-w","volume":"24","author":"L Hoffmann","year":"2024","unstructured":"Hoffmann L, Michels S, Eandi C, Karam MA, Figueiredo ECO, Hatz K. Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series. BMC Ophthalmol. 2024;24(1):520.","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"1344_CR18","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/09273948.2025.2476061","volume":"33","author":"MH Nowroozzadeh","year":"2025","unstructured":"Nowroozzadeh MH, Hajipourkhorasani M. Increased risk of retinal vasculitis may be associated with aflibercept 8 mg: a pharmacovigilance analysis of the FAERS database. Ocul Immunol Inflamm. 2025;33(6):1056\u20138.","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"1344_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.ophtha.2024.04.014","volume":"131","author":"DS Borkar","year":"2024","unstructured":"Borkar DS, Parke DW 2nd, Lee AY. Leveraging real-world evidence to enhance clinical trials. Ophthalmology. 2024;131(7):756\u20138.","journal-title":"Ophthalmology"},{"key":"1344_CR20","unstructured":"Wong TY. Aflibercept 8 mg in neovascular AMD: 156-week results from the PULSAR extension. Macula Society Meeting; Florida, USA2025, February. p. https:\/\/share.google\/iRquNgeVVhLAB2UMO."},{"key":"1344_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-025-01239-3","author":"N Bartolomeo","year":"2025","unstructured":"Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Crozat B, Barry MP, et al. Early outcome analysis of intravitreal aflibercept 8 mg treatment in Na\u00efve patients with neovascular age-related macular degeneration using artificial intelligence. Ophthalmol Ther. 2025. https:\/\/doi.org\/10.1007\/s40123-025-01239-3.","journal-title":"Ophthalmol Ther"},{"issue":"7","key":"1344_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2018;2(7):645\u201353.","journal-title":"Ophthalmol Retina"},{"key":"1344_CR23","doi-asserted-by":"crossref","unstructured":"Grimaldi G, Ambresin A, Pfister IB, Schild C, Plasencia C, Hatz K, et al. One-year outcomes after switching to faricimab in eyes with pretreated neovascular age-related macular degeneration: a swiss retina research network report. Ophthalmol Retina. 2025.","DOI":"10.1016\/j.oret.2025.03.015"},{"issue":"1","key":"1344_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.oret.2020.09.025","volume":"5","author":"CU Okeagu","year":"2021","unstructured":"Okeagu CU, Agr\u00f3n E, Vitale S, Domalpally A, Chew EY, Keenan TDL. Principal cause of poor visual acuity after neovascular age-related macular degeneration: age-related eye disease study 2 report number 23. Ophthalmol Retina. 2021;5(1):23\u201331.","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"1344_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ajo.2014.11.022","volume":"159","author":"CA Arcinue","year":"2015","unstructured":"Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(3):426-36.e2.","journal-title":"Am J Ophthalmol"},{"key":"1344_CR26","doi-asserted-by":"crossref","unstructured":"Sisk RA. Occlusive retinal vasculitis after aflibercept 8\u00a0mg injection for wet macular degeneration. Retin Cases Brief Rep. 2025.","DOI":"10.1097\/ICB.0000000000001757"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01344-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01344-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01344-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:42:27Z","timestamp":1775133747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01344-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1344"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01344-x","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Justus G. Garweg: Advisor and speaker for several pharmaceutical companies. Contributes to several international industry-sponsored clinical studies in the fields of retinal disease and uveitis (AbbVie, Bayer, Novartis, Roche). This manuscript is independent of these activities. Marion R. Munk: Consultant for AbbVie, Allergan, Acucela, Aviceda Therapeutics, Alimera, Bayer, LumiThera, OD-OS, Isarna Therapeutics, Roche, Novartis, Oculis, OcuTerra, genesight Therapeutics, Kubota, B\u00f6hringer-Ingelheim, EyePoint, Ocular Therapeutix, Apellis, Astellas, Zeiss, RetinAI, Dandelion. Andreas Weinberger: Payed consultant and\/or lecturer for AbbVie, Apellis, Bayer, Roche, Sandoz. Sandrine Zweifel: Consultant and advisor for Alcon, Allergan, Apellis, Bayer, Endogena, Novartis, Roche, and Zeiss and grant support from Bayer, Novartis, and Roche outside the submitted work. Gabor M\u00e1rk Somfai: consultant for Apellis, Allergan, Astellas, Bayer, Carl Zeiss, Roche. Nicolas Feltgen: Consultant and lecturer for Apellis, Bayer, Novartis, Roche, Heidelberg Ing. Katja Hatz: Advisory board participant and lecturer for Apellis, Bayer, Roche, AbbVie\/Allergan, Novartis; contract research and\/or grant support for Bayer, Roche, AbbVie\/Allergan, Novartis. Moreno Menghini: consultant for Alcon, Apellis, Astellas, Bayer, and Roche. Lecturer for Bayer and Roche. Grant support from Bayer and Roche. Aude Ambresin: consultant for Bayer, Novartis, Roche, Apellis, and EarlySight; lecturer fees from Optovue, AbbVie, Novartis, Bayer, Roche, Apellis, Astellas, and RetinAI. Chiara M. Eandi: advisory board participant and lecturer for AbbVie, Apellis, Astellas, Bayer, and Roche. Alice M. Kitay, Anne Tillmann, Isabel Pfister, Christin Schild, Matteo Bonanata, Katharina Heck, Tahm Spitznagel, Felix Gabathuler, Nicolo Bartolomeo, Simon Magnin, Jordan L\u00f6liger, and Malaika M. Kurz-Levin have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by all participating ethics committees, led by the Ethics Committee of the canton of Berne (registration no. 2024\u201301026). Coded patient data were included based on general or specific informed consent, in line with the International Council for Harmonisation Good Clinical Practice (ICH-GCP) E6 guidelines, the Declaration of Helsinki, and Swiss law.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}